Johnson & Johnson
Prices may be delayed up to 20 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| JNJ.BA | JNJ.NE | 4578.T | LLY | MRK | 4552.T | |
|---|---|---|---|---|---|---|
| Market cap | 340.28T | 849.61B | 6.56T | 1.13T | 369.78B | 64.91B |
| P/E (TTM) | 14.9 | 23.5 | 16.4 | 42.7 | 119.0 | 79.4 |
| Forward P/E | — | — | 24.1 | 26.9 | 16.1 | 14.5 |
| Price/book | 7.8 | 0.7 | 2.0 | 33.4 | 8.8 | 1.5 |
| Dividend yield | 1.86% | 2.49% | 1.62% | 0.54% | 2.29% | 3.83% |
| 1-year change | +36.69% | +40.84% | +50.29% | +58.00% | +69.27% | −16.35% |
| Today | +2.62% | −0.82% | +1.13% | −1.01% | +1.07% | +1.92% |
The closest companies by business and industry (Drug Manufacturers - General). Prices may be delayed up to 20 min.
Latest news
All JNJ.BA news ›The Zacks Analyst Blog Highlights Abbott Laboratories, Johnson & Johnson, Stryker, Waste Management and Republic Services
The Globe and Mail The Zacks Analyst Blog Highlights Abbott Laboratories, Johnson & Johnson, Stryker, Waste Management and Republic Services Chicago, IL – October 20, 2026 – Zacks.com announces the list of stocks featured in the Analyst…
Johnson & Johnson Stock Could Be a Defensive Play for the Years Ahead
Johnson & Johnson just posted a quarter that sent shares sliding despite a headline beat, yet analysts keep piling into the bull camp with price targets well above current levels. Here is what the numbers actually say about whether this……
What Companies Does Johnson & Johnson Own?
Get step-by-step guidance on investing in Johnson & Johnson stock and learn the ins and outs of this healthcare company. Eli Lilly, Johnson & Johnson, and AbbVie are the largest companies in the healthcare sector. Companies on the front…
Johnson & Johnson to Showcase the Future of Surgical Intelligence at Abu Dhabi Future Health Summit 2026
At the Summit, Johnson & Johnson will highlight innovations across its surgery portfolio and convene discussions on surgical intelligence. Attendees will experience innovations including the MONARCH™ platform and the Polyphonic™ digital…
Johnson & Johnson Launches Next-Generation Shockwave™ C2 Aero Fly Coronary IVL Catheter, Cutting IVL Treatment Time in Half
Built to Meet Growing Cath Lab Demand Designed to Treat Calcified Coronary Disease More Efficiently Shockwave C2 Aero Fly enables physicians to treat complex calcified coronary disease faster while enhancing the patient treatment…
Johnson & Johnson (JNJ) Stock Analysis: Evaluating the 9.33% Potential Upside
Currently trading at $255.56, Johnson & Johnson’s stock is positioned within a 52-week range of $186.00 to $278.43. The slight price change of 0.01% reflects a subtle market response, yet analysts are optimistic about its trajectory. The…
Johnson & Johnson talc charge wipes out 96% of quarterly profit
Keith Howard is a financial journalist specializing in stock market analysis and investment strategies. With over 15 years of experience covering equity markets, earnings reports, and market trends, he brings clarity to complex financial…
Has Johnson & Johnson Stock Become A Different Bet?
Johnson & Johnson Now Talks Up Cancer Drugs During the fiscal Q3 2026 call, executives outlined their ambition to become the number 1 oncology company and the leader in cancer medicines by 2030. The message a year earlier was about…
JNJ Investors with $100,000 in Losses Have Opportunity to Join Johnson & Johnson Fraud Investigation with SBS Law
The National Law Review JNJ Investors with $100,000 in Losses Have Opportunity to Join Johnson & Johnson Fraud Investigation with SBS Law LOS ANGELES--(BUSINESS WIRE)--$JNJ--Schall, Brown & Schwartz LLP (“SBS”), a national shareholder…
Johnson & Johnson’s Dividend Machine Is Running. Can Earnings Keep Up?
Johnson & Johnson’s latest results show resilient pharmaceutical growth but softer medical-device sales, raising a key question for dividend investors: can its competitive moat justify a premium valuation? However, even a company like J&J…
From articles in the 4Search news index.